Cryoport (NASDAQ:CYRX) Full Year 2024 Results

Key Financial Results

• Revenue: US$228.4m (down 2.1% from FY 2023).
• Net loss: US$122.8m (loss widened by 14% from FY 2023).
• US$2.49 loss per share (further deteriorated from US$2.21 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cryoport EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 28%.

The primary driver behind last 12 months revenue was the Life Sciences Services segment contributing a total revenue of US$163.7m (72% of total revenue). Notably, cost of sales worth US$128.8m amounted to 56% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$148.0m (67% of total expenses). Explore how CYRX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US.

The company's shares are up 31% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Cryoport (at least 1 which is a bit concerning), and understanding them should be part of your investment process.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.